Lanolin is a pharmacologically active or chemically reactive compound used in pharmaceutical manufacturing as an active ingredient, synthetic intermediate, or process reagent, requiring toxicological characterisation to establish protective occupational exposure limits. Available data from in vitro and in vivo studies are evaluated in a weight-of-evidence assessment to identify the critical study, the most sensitive adverse effect endpoint, and the applicable NOAEL or LOAEL that serves as the point of departure for PDE calculation. Data gaps are addressed through read-across from structurally related compounds, (Q)SAR predictions, or application of TTC defaults where scientifically justified.
Study duration uncertainty factor F3 in PDE derivation for Lanolin compensates for the data gap between the duration of available toxicology studies and the chronic lifetime pharmaceutical exposure scenario. F3 equals 1 when a ≥12-month rodent study or 9-month non-rodent study forms the basis; F3 is set at 2 for 6-month studies, 5 for 13-week sub-c
